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I. Introduction
Unlike most industries, the successes and growth of pharmaceutical companies (pharma
companies) can often lead to the pharma companies’ own vilification by consumers and health
care practitioners alike.1 The role of pharma companies serving as ‘Public Enemy Number One’2
is perpetuated by stigmas associated with the great unknown of drug research and production.3
This animosity towards these companies also arises from lingering questions the general public
has when considering the long-term effects of prescription drug use.4 Some patients further fear
that big pharma is out to get the bottom dollar, or that pharma companies are not worried about
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misleading consumers into buying the ever-increasing amounts of drugs pumped into the
market.5
In general, pharma companies have a problem with their reputations in the United States
(“U.S.”).6 The U.S. is one of only two countries in the world that legally allows pharmaceutical
companies to advertise directly to consumers through the use of direct-to-consumer
advertisements (“DTC ads”).7 While patient-consumers are inundated with a wave of different
drug advertisements each day, it is possible that consumers can forget who and what is behind all
these ads. Pharma companies invest time, money, and resources in their research, development,
manufacturing, marketing, advertising, and selling of drugs.8
All of these investments can be viewed as a means to support and maintain an interest
many pharma companies have – equalizing and bettering public health.9 While this is not the
only goal of pharma companies when they make the necessary investments to create and launch
drugs into the market; indeed, it is still one that links pharma companies’ interests with
considering the greater public health.10 DTC ads are pivotal to the promotional successes of
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pharmaceuticals.11 Unfortunately, the hazards of misrepresenting public safety and health risks in
these short bursts of audial/visual persuasion continues to put DTC ads in the hot seat.12
DTC ads for pharmaceuticals are not only valuable to the success of pharma companies
but they are also key in the empowerment of consumer-patients.13 DTC ads have increased
conversations between physicians and patients, and normalized inquiries about ailments and
diseases that would otherwise go unnoticed or undiscussed between physicians and patients.14
Furthermore, due to an extensive history of legislation, regulation, and case law, the commercial
speech of DTC ads is locked down in U.S. history books indefinitely as protected commercial
speech under the First Amendment (so long as it is truthful and non-misleading).15 This article
seeks to look at historical attempts to regulate DTC ads in efforts to determine whether
regulatory agencies and guidelines can reduce the negative effects of DTC ads, while still
enjoying the ads’ benefits.
II. What is Direct-to-Consumer (“DTC”) Advertising and How is it Related to Public
Health?
DTC ads are a powerful tool and method of communication used by pharmaceutical
companies to broadcast prescription drug information (including the major statement, risks
associated, any boxed warnings, counterindications, and other vital information) via different
media outlets (such as radio, television, or the Internet).16 These ads are a key resource aiding in
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the success of pharma drug campaigns, as prescription drug information is shared directly to
consumers to promote and educate patients on alternative treatments and drug options.17 These
ad campaigns are often exceedingly expensive for pharma companies, and require marketing and
advertising personnel, as well as legal advisors to ensure compliance with FDA regulatory
standards.18
Due to unclear and contradicting standards from the FDA, pharma companies often must
fill in the gaps in DTC ad development.19 As standards can be confusing, it comes as no surprise
that DTC ads can frequently lead to misunderstanding for consumers who struggle to digest and
comprehend the material transmitted through these ads.20 From the pharma perspective, DTC ad
production requires a great amount of time and effort that is often filled with pressures to
successfully release an ad campaign that passes muster for both regulating agencies and public
opinion alike.21 Unlike general product advertisements, DTC ads demand the utmost care and
management, as the product at hand can have potentially detrimental consequences to society: a
drug impacting public health and safety.22
Public health is often defined as “the science and art of preventing disease, prolonging
life, and promoting physical health and efficiency through organized efforts of society.”23 It is
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true that the end goal of pharma companies’ is often to sell their product(s) on the market, and
utilize DTC ads to increase sales.24 However, with these ads and sales comes a greater
interaction between pharma companies and consumers that can lead to a change in the public
health of the nation. This change and development must be observed and regulated. Placing the
onus of mitigating the negative effects of DTC ads on pharma companies can be far too great a
burden for a single industry to do on its own. It is also important to note that when consumers
purchase drugs and increase the profits of pharma companies it can lead to a greater amount of
funding that can go into continued research and development of alternative treatments and drugs.
What is unique about DTC ads, their regulations, and the impacts they have on public
health is the time sensitive nature of the development of ads as well as the regulations.25 With
each moment of time that passes, a facet of a disease or disorder is developing and morphing.26
New drugs are being researched, tested, manufactured, and released onto the market. Messages
and ideas are being shared to a broad audience that carry varied intentions and meanings
pertaining to pharmaceuticals and their uses. The conditions for creating and enforcing
regulations in this field are so adaptable and volatile, that it can seem as if law and regulations
are two steps behind the progress of medicine, working to catch up with the constant evolution
and innovation. All these factors amount to a high-stake, high-stress environment of working to
balance the public health and safety risks and benefits in regulations, while allowing pharma
companies to successfully sell and create more products.
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How DTC ads are viewed and interpreted can vary based on individual experiences, and
ultimately raises the public health concern of what role these ads play in “inform[ing],
educat[ing], and empower[ing] people about health issues” to the community at large.27
Admittedly, consumer comprehension of these drugs’ risks and benefits can be impacted by
pharma companies’ own efforts to downplay risk or oversell benefits.28 At the same time,
pharma companies can struggle with meeting FDA guidelines for simple language in their ads to
limit consumer confusion, which can also lead to obfuscating the risks and benefits of the
drug(s).29 The tangled webs and balancing act of satisfying both the FDA and the consumer can
appear next to impossible to navigate for pharma companies.
The benefits of DTC ads are not just for the pharma company. DTC ads lead to the direct
targeting of patient-consumers, which has increased the dialogue between patients and their
physicians.30 Patients are empowered to seek medical advice from physicians pertaining to
diseases and ailments that have been brought to their attention by these DTC ads.31 Patients feel
more equipped and more confident to reach out to their physician and speak about diseases and
disorders that they were either previously unknowledgeable about, or too afraid/insecure to bring
forward to the table.32 Viewing the symptoms of a disorder on a DTC ad can also normalize and
decrease the stigmas associated with diseases and disorders, especially ‘invisible disabilities’
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regarding mental health.33 This can ease the stress that patient-physician conversations could
generate for individuals seeking medical help.
Normalizing these discussions is also particularly helpful in achieving the public health
interest of equalizing health treatment and access to patients of different socioeconomic
backgrounds.34 Indeed, “patients with lower incomes and education levels who are less likely to
seek medical care, in general, were more likely to see a doctor after seeing DTC prescription
drug ads.”35 This increased dialogue also suggests that patients are more informed about
diseases/conditions and possible or alternative medical treatments.36 In fact, 48% of doctors
agree that DTC ads "inform, educate, and empower" patients, as established in an FDA survey.37
DTC ads also serve as reminders to patients to stay on track of medication/treatment plans as
well as seek out alternative treatment methods that they might not otherwise have known about.38
This is extremely beneficial in achieving a public health goal of increasing the quality of care
and quality of health of the general population.39
Unfortunately, positive effects can also bring negatives ones as well, and that is certainly
the case for DTC ads. For one, DTC ads can lead to misinformed patients.40 DTC ads serve as a
double-edged sword by providing consumers with a wide breadth of new and valuable
information about pharmaceutical products.41 All the while, this influx of data (often riddled with
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necessary but complicated medical and legal jargon) can increase the chances that this
information can also be misinterpreted or misunderstood.42 Despite FDA efforts to regulate the
vocabulary and verbiage used in these advertisements, the brief duration of the advertisements,
coupled with often flashy and distracting storylines, can divert the consumer and detract from
information comprehension and retention.43 The general population does not take the time to
assess the accuracy and representation of facts shared in pharmaceutical ads, and is likely to be
susceptible to misunderstanding and misinterpretation of the risks that are associated with the
drugs seen on the ads.44 This reality increases the risk of misleading and deceptive information
being shared with all consumers – both informed and uninformed.
Additionally, long-term health and safety risks of prescription drugs are often not
determined upon the release of DTC ad campaigns.45 This can lead to a misunderstanding of the
current and future harms and counterindications that could arise in the consumption of the
advertised drugs.46 In 2011, a survey found that 43% of patients believed drugs advertised on
DTC ads were 100% safe when being marketed.47 This suggests that portions of the general
population have misinterpreted the risks of the drug advertised, and could be placing their health
at risk because of this misguided trust in what consumers hear and see in DTC ads.48
Another concern is raised that the popularization of DTC ads results in the over-filling
and over-consumption of prescription drugs.49 This concern has been raised for attention deficit
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hyperactivity disorder (ADHD).50 In 2014, ADHD medication prescriptions were written
approximately 25 times more frequently in the United States than in the United Kingdom (where
DTC ads are not allowed), and this number keeps rising.51 This one example reflects the growing
concern in the public health field that there could be an increase in the usage of prescription
medication correlated to the increase in patient-physician conversations about these drugs.
While some experts argue that the dramatic rise in prescription filling is clear evidence
that the ADHD indication is being diagnosed and medically treated (for children, in particular)
far surpassing reasonable rates, proponents of DTC ads argue otherwise.52 These individuals
argue that the risk of overfilling prescriptions is outweighed by the triumphs of prevention, early
detection, mitigation, and treatment of illnesses and disorders.53 Proponents argue that DTC ads
have normalized symptoms of ADHD and have empowered children and adults to approach
physicians and seek pharmaceutical drug assistance with these ailments.54 In the end, DTC ads
for ADHD drugs and other pharmaceuticals must fight to balance the public health and safety
risks and benefits, and how to best share that information with the public.
III. FDA guidelines and regulation
Since the information shared through DTC ads implicates the general public health, this
information is regulated in a somewhat similar fashion as public health programs would be
regulated. Public health programs are influenced, if not generally controlled, by a federal
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government agency.55 In this case, the Food and Drug Administration (“FDA”) is the leading
government agency that regulates DTC ads pursuant to the Food, Drugs & Cosmetics Act
(“FDCA”).56 It is the FDA’s responsibility to oversee advertising for prescription drugs (to note,
this is not applicable for over-the-counter medication).57 Furthermore, the FDA’s Office of
Prescription Drug Promotion (“OPDP”) is the subsection of the FDA that reviews and provides
advisory comments (oftentimes, in the form of either Untitled or Warning enforcement letters)
regarding these pharmaceutical DTC ads.58
In efforts to hold pharmaceutical companies accountable, the FDA has set forth standards
for what drug ads must tell consumers.59 DTC ads are required to: “(1) Not be false or
misleading; (2) Present a fair balance of risk and benefit information; (3) Include facts that are
material to the product’s advertised uses; and (4) Include a brief summary of every risk described
in the product’s labeling.”60 This can be done by requiring drugs ads to express to consumers
three key things: “(1) at least one approved use for the drug; (2) the generic name of the drug; (3)
and all the risks of using the drug (or under certain circumstances, only the most important).”
Though these standards and criteria can be useful in mitigating some of the negative
consequences of DTC ads, scholars argue that retrospective review of these ads can be injurious
to the consumers and pharma alike.61 Consumers, empowered by what they view in DTC ads, are
often persuaded by the images and storyline that provide hopes for a ‘cure-all’ or at least a
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potential solution to the ailments they are facing. Patients are often eager to reach out to their
physicians about a new treatment, rather than wait for a period of time in hopes that the FDA has
gotten around to reviewing and assessing these ads for any misleading information presented. If
OPDP was to review DTC ads prior to their initial release, it could circumvent much of the
confusing conversations that are held between physicians and patients.
In the meantime, pharma companies make great investments in DTC ad campaigns, and
often feel it necessary to release these ads as soon as possible to have their product gain traction
and sell in the market.62 A delay in the release of an ad campaign could be detrimental to the
success of the product launch and lead to financial struggles for the company. The costs incurred
can escalate even more when the FDA then issues an enforcement letter demanding the company
take down these expensive ad campaigns and release new ones.63 The requirement to apologize
and clarify for mistakes made by the company in the initial DTC ad campaigns in a later ad
campaign can also cost the pharma company credibility and reputation points.64 This is
especially detrimental where pharmaceutical companies already struggle with maintaining
positive reputations and credibility in the eye of the consumers.65
All of these costs incurred by pharma companies implies that they are unlikely to want to
continuously recreate drug ads repeatedly. It is in both to the pharma companies’ and the
consumers’ benefit to work with FDA regulations and guidelines to prepare and disseminate
meaningful and truthful advertisements the first time around. Unfortunately, the history of DTC
ads regulations and guidelines has been as complicated, if not more, than it is now.
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IV. A Look at Pharmaceutical Advertising Regulations Over Time
It is critical to look at the history of pharma advertising to identify patterns and efforts
that can be used presently to reduce the negative effects DTC ads may have. The start of federal
DTC drug regulations can be seen in the Progressive Era, as a means to regulate the few ‘ethical’
and ‘on the book’ drugs that were then on the market.66 At this time, the 1906 Pure Food and
Drug Act67 applied, as it prohibited interstate transport of unlawful drugs.68 Elements reminiscent
of portions of this statute will continue and evolve into modern regulations to date.
The Pure Food and Drug Act is rooted in protections of proper (or rather, inappropriate)
labeling on food and drugs.69 While modern FDA regulations often relates to premarket approval
and uses, recently there has been a shift of concern once again towards labeling (e.g., off-label
uses of pharmaceuticals).70 The Pure Food and Drug Act also required that “no detail of a drug
label could be false or misleading and even required labels to list the existence and/or
concentration of eleven different ‘dangerous substances’.71 Some controversy arose early on
regarding the reliability of therapeutic claims of drugs, as U.S. v. Johnson ruled that it was not
prohibited to falsely advertise therapeutic claims.72 Ultimately, in a showing of the push and pull
between the Court and Congress, the Shirley Amendment overruled Johnson by prohibiting
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claims that could ‘defraud the purchaser’.73 This debate continues into modern day concerns of
how to best avoid having DTC ads misrepresent the risks and benefits of a drug.74
In 1938, the FDCA was passed as a statutory recognition that consumers, who were
generally self-medicating at the time, brought about public health concerns in their use of
pharmaceuticals without the presence of further federal regulations.75 While the FDA had
recognized over twenty dangerous substances that could not be obtained over-the-counter
(“OTC”) or without prescription, it had become apparent that patients obtaining pharmaceuticals
were at risk. In turn, the FDCA worked to expand the FDA’s authority in drug regulation and
mandated, for the first time, that drugs be proven safe for consumers by obtaining approval
before being marketed.76 FDCA also continued to expand FDA drug labeling requirements to
include more than the name and ingredients of the drug.77 The initial FDCA labeling
requirements can be likened to labels consumers see today in OTC drug labels.78 Unfortunately,
the FDA’s effectiveness in regulating through the FDCA was greatly limited by the passage of
the Wheeler Lea Act in 193879, which granted jurisdiction and authority of drug advertising to
the Federal Trade Commission (“FTC”).80
Historically, pharmaceutical companies could only advertise their products to
physicians.81 This prevented direct communication and education to the patients, who were left
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underinformed of potential diagnoses and treatments to the ailments they were facing.82 This also
made diversifying the pool of consumers and broadening the base of patients limited at the start
of pharmaceutical development.83 Now, with a broader pool of consumers, there is the chance of
increased understanding in the uses and effects of prescription drug consumption, if and when
post-marketing research is conducted. With a larger pool of consumers, research findings could
be considered more inclusive and more in-depth.
Additionally, the unclear distinction between OTC and prescription drugs in regulations
led to general confusion and varied uses of drugs prescribed by the physicians.84 It was with the
passage of the Durham Humphreys Amendments (“DHAs”) to the FDCA that a statutory
definition of prescription drugs was finally passed and could lend itself to better regulations of
the drugs in the future.85 However, the DHAs backfired in that pharmaceuticals classified as
prescription drugs soon saw less of the full product labeling required of OTC drugs.86 The
struggle to regulate what safety risks and drug information was being shared to consumers has,
and always will be, a battle for pharma companies and the FDA as a regulatory agency.
A. Federal Policy on Pharmaceutical Marketing in the 1960s and Beyond
Ultimately, the involvement and regulation of the FDA in DTC ads is one of the reasons
these ads have become so omnipresent in the American market system.87 The FDA garnered its
expansive authority in advertising regulations in 1969, when it passed a regulation requiring
advertisements contain a “true statement of information in brief summary relating to side effects,
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contraindications, and effectiveness” (FDA/DHHS 1969)88. Additionally, DTC ads must present
a “fair balance” between information presented about the drug's side effects and
contraindications and the drug’s effectiveness.89 The regulations even go so far as to explain to
consumers and pharma companies how an advertisement could be considered false, unbalanced,
or otherwise misleading.90
The FDA’s authority in regulating pharma drugs is one of the agency’s primary means in
meeting a main goal the FDA has in safeguarding public health and safety in the use of
pharmaceuticals.91 This interest, coupled with the growing Patient’s Rights Movement in the
1970s (whose goal was to require physicians to provide patients with alternative treatment plans)
launched the wave of pharma advertising that is regulated in part by the consideration of the
overall public health and well-being.92
B. First Amendment Protections
DTC ads are here to stay in the American market system, with both their pros and cons,
largely because these ads can be considered protected speech under the First Amendment.93 The
First Amendment is implicated in the use of DTC ads, as the FDA seeks to regulate meaningful
and truthful information pharma companies share within these ads, in hopes to limit the negative
public health effects these ads can have.94 With DTC ads right at the fingertips of consumers,
concerns about mass sharing of complicated and risky medical information compete against First
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Amendment guarantees and protections of freedom of speech (advertisements as forms of
commercial speech).95
First Amendment protections extend to commercial speech, or speech related to the
economic interests of the speaker and its audience.96 A complete ban of commercial speech not
only injures the commercial interests of the producer of speech, but also that of the consumers
who have a societal interest in obtaining the fullest amount of information and then choosing
what they do and do not agree with.97It is not only in the pharma’s interests to advertise their
drugs, but also in the consumers, who have their best interests in mind, in digesting information
within advertisements.98
In considering how DTC ads can now be better regulated to minimize the negative effects
that they can have on the general public health, it is important to look at how the regulation of
commercial speech is treated in general. Central Hudson Gas & Elec. Corp. v. Pub. Serv.
Comm’n of New York sets forth a standard that if commercial speech is “neither misleading nor
related to unlawful activity”, government and agency’s regulatory authority is limited.99 If the
State then asserts a substantial interest in restricting this commercial speech, the method of
regulation must then be in proportion to that interest, specifically designed to meet that particular
State goal.100 A framework of these criteria is as follows: “(1) the restriction must directly
advance the State interest involved; the regulation may not be sustained if it provides only
ineffective or remote support for the government's purpose; and (2) if the governmental interest
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could be served as well by a more limited restriction on commercial speech, the excessive
restrictions cannot survive”.101
While Central Hudson is an electrical utilities company that brought suit against the NY
Public Service Commissioner for regulations that wholly banned promotional electrical
advertising, the concept against banning commercial speech has also extended its application to
include DTC ads.102 A brief outline of Central Hudson framework from above for application in
future considerations of commercial speech is as follows: whether,
“(1) the expression is protected by the First Amendment. For commercial speech
to come within that provision, it at least must concern lawful activity and not
be misleading; (2) the asserted governmental interest is substantial; and if both
inquiries yield positive answers, (3) the regulation directly advances the
governmental interest asserted, and (4) it is not more extensive than is necessary
to serve that interest.”103
In Thompson v. Western States Medical Center,104 the Supreme Court applied the Central
Hudson105 framework in determining whether FDA regulations on compounded drug advertising
was a violation of First Amendment protections.106 Thompson notes that it is the burden of the
party wishing to uphold the restriction on the commercial speech to justify such a restriction.107
Thompson stands out as a valuable case for future DTC ad regulations, as the court explicitly
states that hypothesized justifications for State’s interests are not sufficient to impose heightened
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restrictions on commercial speech, unless used on a rational basis review.108 The Central Hudson
standard of review for commercial speech is stricter than rational basis.109 In the case of
Thompson, the court notes that even if the fear that these advertisements would motivate patients
(even those who did not need to risk being exposed to the consumption of unneeded drugs) to
convince their physicians to prescribe these drugs, it still fails as justification for narrow
restriction of advertising as commercial speech.110
This concern of overprescribing without a founded need is one that is still raised amongst
consumers and physicians observing the trends of increased prescription writing and filling
today.111 It can be argued that there is an increased public health and safety risk generated from
the rise in patients seeking prescriptions for drugs that they might not otherwise have needed or
wanted prior to viewing a DTC ad.112 However, proponents of stricter monitoring and regulation
of DTC ads must show that any such interest argued must first surpass that which is found
insufficient here in Thompson, which can be challenging.113
i. First Amendment Application to Off-Label Use Advertisements
Pharma companies are generally prohibited from marketing and advertising off-label uses
(uses of drugs not authorized or recognized within the indications and uses of the formal FDAapproved label).114 Therefore, an off-label use of a drug is any use in which has not been
authorized by the FDA. While pharma companies can try to be cautious in any advertising of off-
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label uses, in fear of repercussions faced by FDA enforcement, it is quite common and very legal
for physicians to prescribe these drugs for off-label uses.115 In fact, “an estimated one in five
prescriptions filled” are for the purposes of off-label uses of prescription drugs.116 Prescribing
off-label is not as peculiar as it may sound; in fact, many times uses of pharmaceuticals are
identified after a drug has underwent FDA approval and label authorization.117
Still, off-label prescribing is not clinically ethical, as the side effects and general
implications of off-label uses have not been extensively studied in FDA-approved studies like
on-label uses have.118 Off label-uses and unintentional advertisements can also expose pharma
companies to legal problems.119 For example, in 2012, GlaxoSmithKline (“GSK”) was fined $3
billion by the federal government, partially due to off-label promotion of several of its drugs.120
This can be particularly challenging for pharma companies that wish to inform consumers and
physicians alike of the potential risks and benefits of off-label uses, especially noting that
physicians legally can, and often, do prescribe medication for off-label uses.121
In Sorrell v. IMS Health122, the Supreme Court ruled a state statute prohibiting the sale,
disclosure, or use of physician prescribing records for the purpose of marketing violated the First
Amendment.123 The court found that the restrictions did not advance a substantial government
interest and that the statute placed an undue burden on commercial speech.124 This line of case
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law continues with United States v. Caronia.125 In Caronia, the defendant appealed a conviction
where he is found “guilty of conspiracy to introduce a misbranded drug into interstate
commerce… [by promoting] the drug…for ‘off-label use’…for a purpose not approved by
the…FDA.”126 Defendant Coronia argued the conviction violated his First Amendment freedom
of speech protection, and the Supreme Court agreed.127 The FDCA prohibits misbranding of a
drug (e.g., product labeling fails to bear “adequate directions for use”).128 This prohibition not
only extends to DTC ads, but, as Caronia shows, representations of off-label uses of drugs as
well.
In Amarin Pharma Inc. v. United States FDA, the court shows a great interest in
promoting the sharing of truthful, non-misleading information, free from the threat of
misbranding charges against the pharmaceutical company by federal regulatory agencies (i.e. the
FDA).129 This interest is similar to that found in the use of DTC ads. Pharma companies
advertise to the general public alternative treatment methods via DTC ads.130 The naturally
restrictive nature of timed DTC ads, combined with the complex subject matter, can render the
danger of misleading risk information a concern, no matter how many restrictions and
regulations are put in place. In the end, the court tends to favor the least restrictive manner of
regulating commercial speech, as applied here.131 In attempts to mitigate the negative effects of
DTC ads, it is important to assess and determine how restrictive the effort would be to the
commercial speech, and if it was ‘more extensive than necessary’.132
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Hypothetically, if Congress was to pass a law that prohibited pharma companies from
advertising directly to consumers, then a claim for violation of the First Amendment protection
of freedom of speech would have to be brought to court. Using the Central Hudson framework,
legal representation, including attorneys representing pharma companies, would argue first and
foremost that a DTC ad is an expression protected by the First Amendment. DTC ads contain
valuable advertising information on new drugs that is intended to inform consumers of
alternative treatments on the market. The content of DTC ads has been established to be lawful
activity, and so long as this information is truthful and not misleading by following FDA
guidelines, the first step of the Central Hudson framework can be considered satisfied.
The second step would then be to consider if the asserted governmental interest is
substantial. With support from Thompson, concerns about consumer enthusiasm for new drugs
that could lead to overprescribing medication is not a justified argument. Such an argument
belittles the reality that physicians are skilled in their profession as to not be swayed by patient
persuasion, and at the same time, patients are entitled to speak their minds and interests to
physicians. Another possible governmental interest, misinterpreting risks of drugs in DTC ads,
can be considered substantial as it is a public health implication that consumers are not
comprehending the extent and degree of risks presented in DTC ads.
The third and fourth steps would be to consider whether the regulation directly advances
the governmental interest asserted, and whether such a regulation is not more restrictive than
necessary to serve that interest. Case law suggests that a total ban on commercial speech violates
protected First Amendment freedom of speech rights. Even in the event that a regulation was to
restrict and not totally ban pharma companies from advertising directly to consumers, the Court
will still refer to commercial speech case law when overruling prohibitions on advertising of

drugs. For these reasons, it is unlikely that legislative regulations of DTC ads will be successful
in achieving the desired result of reducing the harmful effects viewing DTC ads can have on
consumers.
ii. Counter-advertising
When it comes to the advertising of products that prove to be a heightened public health
risk, the tobacco industry and counter-advertising created against its products, shines as an
example of mitigating health risks. When the FDA recognized the public harm caused by
tobacco and tobacco-based products, it took measures in passing the Family Smoking Prevention
and Tobacco Control Act.133 The landmark case of Discount Tobacco City & Lottery, Inc. v. U.S.
held that under the Central Hudson test, the deceptive nature of tobacco products advertisements
that deceitfully promoted health claims, outweighed the interest of protected commercial
speech.134 This can be a case to look at in the future for examples of restricting First Amendment
protected speech.
In 2014, the Centers for Disease Control and Prevention (“CDC”) identified smoking and
the use of tobacco products as a health and safety concern, which encouraged the agency to
launch and release a national tobacco education campaign.135 A twelve-week campaign had been
previously released in 2012 but was not nearly as effective because of the manner in which the
counter-advertisements were presented then.136 The latest method created two phases that
provided a succession of new and interesting counter-advertisements that educated the public in
smoking risks and health-related issues.137 Then-CDC Director, Tom Frieden, M.D., M.P.H.,
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argued the “TIPS” campaign was extremely cost-effective because it saved not only money, but
also lives.138 In fact, “approximately 17,000 premature deaths from smoking were estimated to
be averted, and 179,000 years of healthy life gained.”139
The CDC was one of, if not the only, agency/company that was able to compete with the
billion-dollar tobacco advertising industry because of its own financial standing, prominence,
and value.140 The CDC triumphed because the effective and constant release of these informative
advertisements was difficult for consumers to avoid and easy to recall back into memory when
consumers were tempted to later reach for that cigarette.
Comparatively, the pharmaceutical industry and its use of DTC ads plays a different role
than that of the tobacco companies’ ads. The objective of pharma companies is not to massproduce and sell a specific product for the use, enjoyment, and entertainment of the general
population, regardless of the health implications as tobacco products posed. DTC ads are used as
a tool to inform consumers of new and innovative products on the market intended to assist and
aid in diseases and disorders that otherwise hamper the greater level of public health within the
U.S. population.141 Therefore, the purpose of the products being advertised in the information
within DTC ads is to aid the public health. The side effects and risks that come with the use of
these drugs are issues that will arise in continuum as far as advancements of medicine is
concerned. But to truly identify DTC ads in the same light as tobacco-products, is to completely
ignore the intents and purposes of medicine and pharmaceutical drugs for the public health as a
whole. While it is also the goal of pharma companies to obtain profits from selling drugs to
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patients, it is ultimately at the choice of the consumer who must still go to a physician and obtain
a prescription for these drugs. To note, while both products largely come down to consumer
choice, ultimately, medications can have both positive and negative effects, while science has
now deduced that tobacco-based products simply have negative side effects.
All these elements considered are important to keep in mind when thinking about what
kind of information and tactics can be utilized in any form of counter-advertising for DTC ads.
At this time, in reviewing all the effectiveness and success found in the scientific promotion and
production fostered by the pharmaceutical industry, it is unlikely that the CDC will determine an
emergent health risk here as it did with the tobacco industry.
Instead of counter advertising against DTC ads, members of the medical profession
should be further expected to clarify and assist in comprehension of information in DTC ads for
the consumers. When it comes to advertising prescription drugs, physicians have notified the
FDA and CDC in different FDA-approved studies that DTC ads are one of many factors
influencing how the doctors will practice and interact with patients.142 DTC ads have empowered
patients to make their own health care decisions and ask far more thoughtful and engaging
questions with their physicians.143 Furthermore, in these studies, physicians have acknowledged
a general industry belief that patients understand “they need to consult a health care professional
about appropriate treatment.”144 With all this considered, it is advisable, and would be greatly
beneficial, if physicians used their duty of care and trusted physician-patient relationship to take
on some of the onus of DTC ad clarification. That is, pharma companies are restricted to a short
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period of time and often confusing guidelines in trying to truthfully represent the risks and
benefits of drugs advertised in DTC ads.
When a patient engages in inquiries regarding drugs seen on DTC ads, a physician could
then further explain the potential risks and benefits of the drug in efforts to clarify any
misunderstandings the patient may have. This can be done in hopes of educating the public
further and clarifying any misconceptions or misunderstandings from viewing the initial DTC
ads. While this might be difficult to accomplish, it could be one of the more successful
alternatives for minimizing the negative effects of DTC ads, without hampering the successes
pharma companies see in the utilization of DTC ads.
C. FDA Enforcement Letters
One struggle the FDA has in supervision and regulation of DTC ads is that the agency
does not review DTC ads prior to their release and viewing by the general public.145
Unfortunately, the parameters set forth by the First Amendment guarantee of freedom of speech
thus far prevents the regulation of information before it has even been disseminated.146 Instead,
the FDA is forced to act quickly (though that is often difficult due to the high submissions and
reviews of different DTC ads) and view the streaming ads for any misleading information or
misrepresentation of risks right alongside the consumers viewing the ads.147 This heightens the
risk of consumers viewing inappropriate ads for violating standards or providing misleading
information. The FDA acknowledges similar sentiments found by the Court in Thompson that
consumers should operate under the impression that not all information has been vetted for the
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absence of misleading or misinforming presentation of risks associated. While the dangers of
having ads viewed by both the FDA and consumers for the first time simultaneously could
significantly support altering the rules set forth to allow the FDA to review advertisements
proactively, it is unlikely to happen given the court precedents.148
The FDA releases warning letters and letters of notice of violation (otherwise known as
untitled letters) to pharmaceutical companies when they are in violation of the criteria set forth
by OPDP.149 When an untitled letter is presented to a pharmaceutical company, the company is
expected to cease distribution of the misleading or misrepresentative information and proceed
with sharing amended information to clarify any misunderstandings in new DTC ad
campaigns.150 Warning letters, as the name suggests, take reprimanding a step further, and
require the pharma company to issue a letter and/or plan of action to the FDA detailing how the
company will remediate any potentially deceptive messages they have shared, and any consumer
mistrust engendered by these ads.151
Enforcement letters fall short in effectiveness because of an agency requirement where,
in order to issue a letter and deem speech to be false or misleading in a DTC ad, OPDP must first
find evidentiary support that the speech is false or misleading.152 This is especially challenging
given that the quantification of false or misleading information can vary greatly, depending on
the level of how informed a consumer is when viewing and processing the advertisement. For
this reason, it seems wise and altogether more productive to create FDA pre-approved language
templates or a form of guidance that pharma companies can use and abide by when initially
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constructing their DTC ad campaigns. If these guidelines and frameworks were then made public
to be used as pre-sets for DTC ads, it could hopefully provide consistency and avoid
misrepresentation or confusion in the future.
Oftentimes, consumers are not even aware that some of the most popular DTC ad
campaigns are taken down or altered in response to the issuance of an FDA Enforcement
Letter.153 Requiring pharma companies to notify consumers of any changes made to their DTC
ad campaigns, pursuant to violations cited by the FDA, can increase the level of awareness and
understanding for the patient-consumer. Making note of these changes in newer campaigns on
top of having pharma companies explaining these changes further in letters released on their
website and social media could likely better inform consumers that there have been changes
made to any misleading information previously presented. This is one way to hopefully mitigate
some of the negative consequences that come with misleading information presented in DTC
ads, in hopes of also maintaining the pharma company’s credibility and success rate.
V. Where Do We Go From Here?
Pharma companies are not the enemies simply because they seek to make a profit in a
challenging industry. DTC ads are used to promote new and innovative drugs in hopes of
appealing to consumers. Exciting messages and catchy music found in all kinds of
advertisements are also found in DTC ads. However, as has already been discussed, a key
component to the pharma industry is the necessity of care in presenting the product facts and
information within these advertisements. While legislation might seem like the best way to
regulate these ads, any state or federal law passed is likely to struggle against the Central
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Hudson framework, which protects First Amendment commercial speech when it is truthful and
not misleading.
Additionally, for the members of the public who are concerned with the risk DTC ads
may pose in popularizing prescription drugs, and potentially leading to the abuse of these drugs,
the FDA released a statement on July 1, 2019.154 In this statement, the FDA promises to work
towards a new goal related to this new topic: Drug Abuse and Dependence Section of Labeling
for Human Prescription Drug and Biological Products - Content and Format.155 One of the goals
of this new guidance is to inform consumers about ways to interpret product labels and
advertisements that will hopefully be updated with safety information regarding abuse, misuse,
addiction, physical dependence and tolerance of the drugs.156 This clear guidance, when
submitted and finalized, could be greatly helpful in clarifying how pharma companies can be
accountable in advertising the warnings and risks associated with their pharmaceuticals, without
hurting the success of their promotional campaigns.
VII. Conclusion
Despite persistent attempts to improve and develop the standard of health in the general
public, pharma companies do not have the best reputations with American consumers. These
companies are leading sponsors and promoters of innovative drug research and development.
With the use of DTC ads, pharma companies work to reach a broad base of consumers, looking
to sell their products for the intended purpose and use advertised. Due to the fact that DTC ads,
as a form of commercial speech, are likely to remain protected by First Amendment, it is
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important for these ads to be meticulously regulated. With these ads, arise concerns of
misrepresentation or misunderstanding of risks and benefits presented. But as is the nature of
medical and pharmaceutical development, the benefits of advertising these products seem to
outweigh the risks.
Most of all, these ads have equalized access to alternative treatment information, by
empowering and educating consumers of all socioeconomic backgrounds of new drugs.
Furthermore, it is in the pharma companies’ interests to produce information that is as accurate
as possible so that the companies can avoid additional expenditure in resources for amended
advertisements and injured reputations. This article seeks to demonstrate the evolution of
regulations, case law, and public awareness to show a path towards mutual sharing of
information and responsibilities for pharmaceutical drug risks and benefits information between
pharma companies, physicians, and patients.

